Equillium Inc at H C Wainwright Global Investment Conference (Virtual) Transcript
All right, everyone. Thank you for coming back. Welcome to H.C. Wainwright's 24th Annual Global Investment Conference. Our next presenter today is going to be Bruce Steel, CEO of Equillium Inc. Bruce, the floor is yours.
Thank you very much. It's a pleasure to be here this afternoon to provide an update on Equillium. Forward-looking statements. I recommend you refer to these at your convenience. So we are a company developing novel therapeutics to treat severe autoimmune and inflammatory disorders of unmet medical need. We have several first-in-class programs now in our pipeline. First is our foundational asset, itolizumab, which is an antibody targeting CD6. We are the leaders in the CD6-targeting biology and the only drug currently in development against this target.
With an acquisition we made earlier this year of another Southern California biotech company, we acquired the novel multi-cytokine targeting platform, including two drug candidates we'll tell you more about. Our lead program, itolizumab,
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
